Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis
ConclusionsOfatumumab may be a therapeutic option for post-transplant FSGS recurrence in patients who respond poorly to rituximab.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
More News: Boys | Kidney Transplant | Kidney Transplantation | Pediatrics | Prednisone | Rituxan | Transplant Surgery | Transplants | Urology & Nephrology